We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation.
- Authors
Zambello, Renato; Bonaldi, Laura; Berno, Tamara; Martines, Annalisa; Sechettin, Erica; De March, Elena; Branca, Antonio; Lico, Albana; Minotto, Claudia; Briani, Chiara; Gurrieri, Carmela; Temporin, Francesca; Battistutta, Claudia; Piazza, Francesco; Cavraro, Monica; Trentin, Livio; Semenzato, Gianpietro
- Abstract
<bold>Introduction: </bold>In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression.<bold>Patients and Methods: </bold>According to time of stopping lenalidomide, patients were subdivided into 3 groups: early stop (ES) (n = 23), when therapy was discontinued within 6 months; intermediate (INT) (n = 23), when therapy was stopped between 7 to 24 months; and long survival (LS) (n = 45), when therapy was maintained for more than 2 years. The median age of the whole cohort was 70 years (range, 42-85 years); 40% had an International Staging System score of 2 or 3.<bold>Results: </bold>High-risk cytogenetic findings, including 1q gain, was reported in 65% ES, 43% INT, and 21% LS. Overall response rate was 63%, with median progression-free survival and overall survival of 33 and 56 months, respectively.<bold>Conclusion: </bold>Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28% of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.
- Subjects
ANTINEOPLASTIC agents; CHROMOSOME banding; MULTIPLE myeloma; PROGNOSIS; THALIDOMIDE; DISEASE relapse; TREATMENT effectiveness; PROPORTIONAL hazards models; RETROSPECTIVE studies; DEXAMETHASONE; KAPLAN-Meier estimator
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2015, Vol 15, Issue 10, p592
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2015.05.003